Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rxo (RXO) Payables (2021 - 2025)

Rxo's Payables history spans 5 years, with the latest figure at $539.0 million for Q4 2025.

  • For Q4 2025, Payables fell 5.11% year-over-year to $539.0 million; the TTM value through Dec 2025 reached $539.0 million, down 5.11%, while the annual FY2025 figure was $539.0 million, 5.11% down from the prior year.
  • Payables reached $539.0 million in Q4 2025 per RXO's latest filing, up from $481.0 million in the prior quarter.
  • In the past five years, Payables ranged from a high of $572.0 million in Q3 2024 to a low of $372.0 million in Q1 2024.
  • Average Payables over 5 years is $482.1 million, with a median of $496.0 million recorded in 2023.
  • The largest YoY upside for Payables was 37.2% in 2024 against a maximum downside of 25.0% in 2024.
  • A 5-year view of Payables shows it stood at $520.0 million in 2021, then decreased by 3.65% to $501.0 million in 2022, then decreased by 17.37% to $414.0 million in 2023, then soared by 37.2% to $568.0 million in 2024, then decreased by 5.11% to $539.0 million in 2025.
  • Per Business Quant, the three most recent readings for RXO's Payables are $539.0 million (Q4 2025), $481.0 million (Q3 2025), and $461.0 million (Q2 2025).